befovacimab

Befovacimab is a fully human IgG2 monoclonal antibody developed as a subcutaneous, non-factor replacement prophylactic treatment for individuals with hemophilia A or B, with or without inhibitors. It binds to the Kunitz 1 and Kunitz 2 domains of tissue factor pathway inhibitor (TFPI), an endogenous anticoagulant protein that inhibits the TF:FVIIa complex and activated factor X in the coagulation cascade. By neutralizing TFPI, befovacimab restores thrombin generation and promotes clot formation regardless of hemophilia type or inhibitor status. Clinical development was terminated after Phase II due to drug-related thrombotic events[1][2][5][6].

Other names

human tissue factor pathway inhibitor-neutralizing antibody (bay 1093884)immunoglobulin g2, anti-(human tissue factor pathway inhibitor) (human monoclonal 1093884 gamma2-chain), disulfide with human monoclonal 1093884 lambda-chain, dimer